Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 1/20 | 0.48 |
| ▸ | MME | P08473 | 4/20 | 0.46 |
| ▸ | ACE | P12821 | 1/20 | 0.46 |
| ▸ | CPA1 | P15085 | 1/20 | 0.46 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.46 |
| ▸ | CTRB1 | P17538 | 5/20 | 0.40 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.38 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.38 |
| ▸ | LTA4H | P09960 | 2/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.37 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30159126 | 1.00 | DPP4 (0.48) | DPP4MMEACECPA1ACE2 | |
| SCHEMBL9701067 | 1.00 | DPP4 (0.48) | DPP4MMEACECPA1ACE2 | |
| SCHEMBL29358853 | 1.00 | DPP4 (0.48) | DPP4MMEACECPA1ACE2 | |
| SCHEMBL31474793 | 1.00 | DPP4 (0.48) | DPP4MMEACECPA1ACE2 | |
| SCHEMBL9242218 | 1.00 | DPP4 (0.48) | DPP4MMEACECPA1ACE2 | |
| SCHEMBL23733547 | 1.00 | DPP4 (0.48) | DPP4MMEACECPA1ACE2 | |
| SCHEMBL30997435 | 1.00 | DPP4 (0.48) | DPP4MMEACECPA1ACE2 | |
| SCHEMBL10620393 | 1.00 | DPP4 (0.48) | DPP4MMEACECPA1ACE2 | |
| SCHEMBL9242204 | 1.00 | DPP4 (0.48) | DPP4MMEACECPA1ACE2 | |
| SCHEMBL29349982 | 1.00 | DPP4 (0.48) | DPP4MMEACECPA1ACE2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-4778846-A | IMMOBILIZATION ON AN OLIGOPEPTIDE MATRICE | SMITHKLINE BECKMAN CORPORATION (US) | 1988-10-18 | — | — | US | claimed |
| EP-0132117-A2 | A process for the preparation of purified vancomycin class antibiotics | SMITHKLINE BECKMAN CORPORATION (US) | 1985-01-23 | — | — | EP | claimed |
| US-12622975-B2 | Peptide-conjugated prodrugs | BRANDEIS UNIVERSITY (US) | 2026-05-12 | — | — | US | disclosed |
| US-20220387610-A1 | PEPTIDE-CONJUGATED PRODRUGS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2022-12-08 | — | — | US | disclosed |
| US-5731320-A | TREATING PATIENT IN NEED OF IMMUNOSUPPRESSIVE, ANTIINFLAMMATORY OR ANTIPROLIFERATIVE THERAPY | ABBOTT LABORATORIES (US) | 1998-03-24 | — | — | US | disclosed |
| US-5643918-A | MACROCYCLIC COMPOUNDS TO REVERSE DRUG RESISTANCE, VIRICIDES, ANTIINFLAMMATORY AGENTS AND FUNGICIDES | ABBOTT LABORATORIES (US) | 1997-07-01 | — | — | US | disclosed |
| US-5563172-A | MICROBIOCIDES, FUNGICIDES, VIRICIDES, ANTIINFLAMMATORY AGENTS, ANTIGROWTH AGENTS | ABBOTT LABORATORIES (US) | 1996-10-08 | — | — | US | disclosed |
| US-4778846-A | IMMOBILIZATION ON AN OLIGOPEPTIDE MATRICE | SMITHKLINE BECKMAN CORPORATION (US) | 1988-10-18 | — | — | US | disclosed |
| EP-0132117-A2 | A process for the preparation of purified vancomycin class antibiotics | SMITHKLINE BECKMAN CORPORATION (US) | 1985-01-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12622975-B2 | Peptide-conjugated prodrugs | PEPD, PAM, VIP | DPP4 43/4885MME 824/4885ACE 1190/4885 |
| US-20220387610-A1 | PEPTIDE-CONJUGATED PRODRUGS | VIP, DNPEP, PEPD | DPP4 73/4885MME 105/4885ACE 486/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.